查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2003030

近距離放射治療設備市場：依產品類型、放射源類型、應用和最終用戶分類－2026-2032年全球市場預測

Brachytherapy Devices Market by Product Type, Source Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，近距離放射設備市場價值將達到 16 億美元，到 2026 年將成長到 18.3 億美元，到 2032 年將達到 40.3 億美元，複合年成長率為 14.03%。

主要市場統計數據
基準年 2025 16億美元
預計年份：2026年 18.3億美元
預測年份 2032 40.3億美元
複合年成長率 (%) 14.03%

本文概述了近距離放射設備在現代腫瘤學中不斷變化的作用，並考慮了臨床需求、創新促進因素和相關人員的決策優先事項。

近距離放射設備仍然是精準放射治療的基礎，它將局部劑量傳遞與優先考慮器官保護和功能預後的臨床通訊協定相結合。目前的技術發展趨勢已超越了成熟的密封源治療，轉向旨在提高劑量分佈均勻性並降低手術複雜性的新型照射系統。臨床醫生、醫院管理者和技術投資者在評估這些治療方法時，會考慮其他體外放射治療方法、患者處理能力的壓力以及支持多學科腫瘤團隊的整合式診療路徑的需求。

透過技術融合、臨床工作流程整合和政策主導的需求，確定將改變近距離放射設備格局的變革性變化。

近距離放射的格局正受到多種因素的共同影響而重塑，這些因素正在從整體上改變臨床工作流程和商業模式。技術融合尤為重要。影像導引定位、施用器模組化以及治療計畫軟體的改進，使得放射源定位更加精準，治療計畫更具適應性，從而降低了治療變異性，並擴大了適用腫瘤部位的範圍。同時，工作流程自動化和混合手術室的出現，減輕了手術室和介入團隊的手術負擔，並提高了門診或日間治療模式的可行性。

評估 2025 年美國關稅對近距離放射治療設備供應鏈、臨床進入途徑和採購彈性策略的累積影響。

2025年起對醫療設備組件和放射源徵收的關稅，為製造商、醫療服務提供者和經銷商帶來了營運和策略上的全新複雜性。採購團隊正在重新審視供應商關係、前置作業時間緩衝和庫存策略，以應對潛在的成本波動，同時確保醫療服務的連續性。因應措施包括重新談判長期供應合約、重組物流路線以及加強與區域供應商的合作，以減輕跨境成本調整的影響。

關鍵的細分洞察，整合產品類型、臨床應用、放射源類型和最終用戶環境，有助於制定有針對性的臨床和商業策略。

以市場區隔為導向的觀點揭示了有助於產品開發和市場進入決策的差異化趨勢。以產品類型（高劑量率、低劑量率、脈衝劑量率）評估，高劑量率系統因其治療效率高且適用於多種臨床適應症而持續吸引投資。同時，低劑量率產品在某些眼科和攝護腺治療通訊協定中仍然至關重要，因為長期植入放射源符合既定的臨床實務。脈衝劑量率 (PDR) 則在基於放射生物學證據和患者個別情況而建議間歇性給藥的特定領域中發揮重要作用。

影響美洲、歐洲、中東和非洲以及亞太地區臨床引進和採購趨勢的區域優先事項和差異化成長要素。

區域趨勢持續影響著不同地區的採用速度和部署策略。在美洲，先進的臨床基礎設施和完善的報銷機制促進了迭代式醫療器材創新技術的早期應用，但成本控制壓力和採購週期要求企業提供令人信服的總體擁有成本 (TCO) 方案。歐洲、中東和非洲地區呈現異質性格局，監管協調、區域採購聯盟以及臨床能力的區域差異塑造了不同的參與策略。與區域經銷商建立合作關係以及採用在地化最佳化的服務模式往往決定企業發展。亞太地區的特點是三級癌症中心的容量快速擴張、微創手術的積極推廣以及本地製造能力的提升，這些因素共同為海外開發商帶來了競爭挑戰和合作機會。

對公司在與主要製造商和創新者的合作、智慧財產權定位以及塑造產業趨勢的服務導向提案等方面的競爭考察和洞察。

近距離放射領域的競爭格局呈現出成熟製造商、新興醫療設備創新者和專業服務供應商並存的態勢。成熟企業憑藉完善的服務網路、良好的監管記錄以及整合了施用器、放射源和計劃軟體的一體化產品組合來脫穎而出。新參與企業則致力於透過創新挑戰現有企業，這些創新主要集中在用戶工程、放射源輸送機制以及可降低現場運算需求的雲端治療計畫等領域。

為行業領導者提供實用建議，以協調研發、經營模式、供應鏈韌性和相關人員參與，從而滿足不斷變化的臨床和政策需求。

產業領導者應優先考慮能夠提升臨床價值並增強業務永續營運的措施。首先，將研發投資與可驗證的臨床結果和使用者工程結合，將加速臨床醫師對科技的採納。這包括優先考慮與影像技術的整合、施用器模組化以及簡化放射源處理流程，從而減少手術時間的差異。其次，企業應制定穩健的供應鏈多元化計劃，包括檢驗的替代供應商和區域生產方案，以降低關稅和物流波動風險，並為醫療服務合作夥伴提供透明的庫存管理工具。

高度透明的調查方法，詳細說明了資料來源、定性和定量分析方法、相關人員訪談和檢驗程序，以確保嚴謹性和可重複性。

本摘要的分析基於以下幾個面向：與關鍵相關人員的對話、技術文獻的整合，以及對公開的監管和臨床指南文件的三角檢驗。主要資訊來源包括對放射腫瘤科醫生、醫學物理學家、採購負責人和臨床工程師的結構化訪談，以檢驗實際臨床工作流程、設備操作挑戰和採購理由。次要資訊來源則著重於同儕審查的臨床結果文獻、設備安全通告和操作指南，以闡明臨床適應症與設備功能之間的關係。

簡明扼要地總結了策略意義、營運風險以及對臨床、商業和監管相關人員。

總之，近距離放射設備在腫瘤醫學領域佔有策略性地位，它兼顧了精準治療、器官保護和治療效率。輸送系統的技術進步、不斷變化的監管預期以及支付方對基於價值的治療結果的重視，共同為設備開發商和臨床採用者帶來了機會和挑戰。供應鏈壓力和關稅導致的成本波動需要積極主動的因應策略。同時，不同地區在培訓和服務提供方面的差異將決定不同醫療保健系統部署的速度和品質。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：近距離放射治療設備市場：依產品類型分類

  • 高劑量率
  • 低劑量率
  • 脈衝劑量率

第9章：按放射源類型分類的近距離放射治療設備市場

  • Cs-137
  • I-125
  • Ir-192
  • Pd-103

第10章：近距離放射治療設備市場：依應用領域分類

  • 乳癌
  • 子宮頸癌
  • 眼部腫瘤
  • 攝護腺癌

第11章：近距離放射治療設備市場：依最終用戶分類

  • 門診手術中心
  • 癌症研究中心
  • 醫院

第12章：近距離放射治療設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：近距離放射治療設備市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章近距離放射治療設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國近距離放射治療設備市場

第16章：中國近距離放射治療設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Becton, Dickinson and Company
  • Biobot Surgical Pte Ltd.
  • Boston Scientific Corporation
  • C4 Imaging LLC
  • Carl Zeiss AG
  • CivaTech Oncology
  • Dexur Inc.
  • Eckert & Ziegler BEBIG SA
  • Elekta AB
  • General Electric Company
  • Guangzhou Perception Vision Medical Technologies Co.,Ltd.
  • Hologic Inc.
  • iCAD, Inc.
  • IsoAid, LLC
  • Merit Medical Systems, Inc.
  • Mick Radio-Nuclear Instruments Inc.
  • Panacea Medical Technologies Pvt. Ltd.
  • Perspective Therapeutics
  • Qfix
  • SeeDOS Ltd.
  • Siemens Healthineers AG
  • Sun Nuclear Corporation
  • Theragenics Corporation
  • Valco Instruments Company Incorporated
  • Varian Medical Systems Inc.
Product Code: MRR-957C47F94A6F

The Brachytherapy Devices Market was valued at USD 1.60 billion in 2025 and is projected to grow to USD 1.83 billion in 2026, with a CAGR of 14.03%, reaching USD 4.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.60 billion
Estimated Year [2026] USD 1.83 billion
Forecast Year [2032] USD 4.03 billion
CAGR (%) 14.03%

Framing the evolving role of brachytherapy devices in contemporary oncology care, outlining clinical imperatives, innovation drivers, and stakeholder decision priorities

Brachytherapy devices remain a cornerstone of precision radiotherapy, combining localized dose delivery with clinical protocols that prioritize organ preservation and functional outcomes. The technology landscape now spans established sealed-source treatments and evolving delivery systems that seek to reduce procedural complexity while improving dosimetric conformity. Clinicians, hospital administrators, and technology investors are evaluating these modalities against competing external-beam approaches, patient throughput pressures, and the need for integrated care pathways that support multidisciplinary oncology teams.

This introduction outlines the principal clinical drivers and innovation vectors that define the current strategic environment. Emphasis is given to how device ergonomics, applicator design, source handling logistics, and adjacent digital solutions are informing hospital procurement cycles and clinical adoption decisions. By framing the discussion around clinical efficacy, safety protocols, and operational integration, the subsequent analysis will connect technological trends with pragmatic considerations that stakeholders must address to maintain competitive and clinical relevance.

Identifying transformative shifts reshaping the brachytherapy device landscape through technology convergence, clinical workflow integration, and policy-driven imperatives

The brachytherapy landscape is being reshaped by several converging forces that collectively alter clinical workflows and commercial models. Technological convergence is prominent: improvements in imaging-guided placement, applicator modularity, and treatment planning software are enabling more precise source positioning and adaptive planning, thereby reducing variability and broadening eligibility across tumor sites. At the same time, workflow automation and hybrid procedural suites are lowering the procedural burden on operating rooms and interventional teams, which makes same-day or ambulatory delivery models more feasible.

Regulatory evolution and heightened attention to radiation safety have prompted manufacturers to invest in sealed-source management and user-friendly shielding solutions, while payers increasingly emphasize value-based outcomes that link procedural choice to patient-reported metrics and long-term toxicity profiles. Simultaneously, supply-chain resilience and localization of component sourcing have grown in importance, catalyzing strategies such as dual-sourcing and regional manufacturing partnerships. These transformative shifts are interdependent: advances in device design influence care-pathway integration, regulatory priorities drive design validation, and reimbursement frameworks affect which innovations achieve scale.

Assessing the cumulative impact of United States tariffs in 2025 on brachytherapy device supply chains, clinical access pathways, and procurement resilience strategies

The introduction of tariffs in 2025 affecting medical device components and radioactive sources has created a new layer of operational and strategic complexity for manufacturers, providers, and distributors. Procurement teams are reassessing supplier relationships, lead-time buffers, and inventory strategies to absorb potential cost fluctuations while preserving treatment continuity. Reaction pathways include renegotiation of long-term supply agreements, reconfiguration of logistic routing, and closer collaboration with regional suppliers to mitigate exposure to cross-border cost adjustments.

Clinically, hospitals and specialized cancer centers are implementing inventory governance and prioritization protocols to ensure uninterrupted access for high-acuity cases. Manufacturers are accelerating efforts to qualify alternative component sources and to validate equivalence across manufacturing sites so that production can pivot without compromising quality assurance processes. In parallel, commercial teams are recalibrating contracting approaches and service bundles to preserve total-cost-of-care propositions for customers, emphasizing integrated training, maintenance, and source management support to maintain clinical partners' confidence amid tariff-driven uncertainty.

Key segmentation insights synthesizing product types, clinical applications, radioactive source varieties, and end-user settings to inform targeted clinical and commercial strategies

A segmentation-led perspective reveals differentiated dynamics that inform product development and go-to-market decisions. When evaluating by product type-High Dose Rate, Low Dose Rate, and Pulsed Dose Rate-High Dose Rate systems continue to attract investment for their procedural efficiency and versatility across multiple clinical indications, while Low Dose Rate offerings maintain relevance for certain ocular and prostate protocols where prolonged source residency aligns with established practice. Pulsed Dose Rate occupies a niche role where radiobiological rationale and patient-specific considerations favor intermittent dose delivery.

Clinical application segmentation across Breast Cancer, Cervical Cancer, Ocular Tumors, and Prostate Cancer highlights where clinical evidence, guideline endorsement, and multidisciplinary team adoption converge to drive demand. For instance, prostate workflows often require integrated imaging and precision applicators, whereas ocular treatments prioritize microsource handling and specialized collimation. Source type distinctions-Cs-137, I-125, Ir-192, and Pd-103-carry implications for handling, half-life logistics, regulatory licensing, and dosimetric planning; institutions weigh these attributes when aligning procurement with clinical caseload profiles. End-user segmentation, covering Ambulatory Surgical Centres, Cancer Research Centers, and Hospitals, signals divergent purchasing models and operational constraints: ambulatory centers seek compact, efficient systems that support high throughput, research centers prioritize modularity and assay capability for investigational protocols, and hospitals require robust service agreements and integration with existing radiotherapy suites. These segmentation lenses should drive product roadmaps, clinical training investments, and commercial articulation of value propositions to ensure alignment with specific user needs and procedural infrastructures.

Regional priorities and differentiated growth enablers across Americas, Europe, Middle East & Africa, and Asia-Pacific that influence clinical adoption and procurement dynamics

Regional dynamics continue to dictate adoption velocity and deployment strategies across distinct geographies. In the Americas, advanced clinical infrastructure and established reimbursement pathways facilitate early adoption of iterative device innovations, although cost containment pressures and procurement cycles require compelling total-cost-of-care narratives. Europe, Middle East & Africa present a heterogeneous landscape in which regulatory harmonization, regional procurement consortia, and variable clinical capacity shape differentiated entry strategies; partnerships with regional distributors and locally tailored service models often determine longer-term presence. Asia-Pacific is characterized by rapid capacity expansion in tertiary oncology centers, aggressive adoption of minimally invasive procedures, and increasing local manufacturing capabilities, which together create both competitive challenges and collaboration opportunities for foreign developers.

Each region demands nuanced approaches to training, regulatory submissions, and post-market surveillance. Stakeholder engagement must account for variations in clinical guidelines, operator skill levels, and facility layouts, and manufacturers should prioritize modular solutions that can be customized to local procedural and infrastructure requirements. Strategic alliances with regional clinical leaders and investment in scalable training programs are essential to transform early interest into consistent clinical utilization across these diverse markets.

Competitive and corporate insights into leading manufacturers, innovator partnerships, intellectual property positioning, and service-oriented propositions shaping sector dynamics

Competitive dynamics in the brachytherapy sector reflect a blend of legacy manufacturers, emerging device innovators, and specialized service providers. Established firms differentiate on comprehensive service networks, regulatory track records, and integrated product suites that bundle applicators, sources, and planning software. New entrants seek to displace incumbents through focused innovation in user ergonomics, source delivery mechanisms, and cloud-enabled treatment planning that reduces on-site computational requirements.

Strategic corporate behaviors include alliance formation with imaging and oncology software vendors to deliver end-to-end treatment pathways, investment in intellectual property around applicator geometries and source encapsulation, and expansion of value-added services such as remote training, maintenance-as-a-service, and inventory management. Observed commercial tactics emphasize proof-of-concept programs with leading clinical centers to accelerate peer-reviewed evidence generation, and tiered pricing models that reflect the heterogeneity of end users from high-volume ambulatory surgery centers to complex tertiary hospitals. These approaches collectively shape competitive positioning and influence purchasing discussions with health system procurement committees.

Actionable recommendations for industry leaders to align research and development, commercial models, supply resilience, and stakeholder engagement with evolving clinical and policy demands

Industry leaders should prioritize initiatives that enhance clinical value while strengthening operational resilience. First, aligning R&D investments to demonstrable clinical outcomes and user ergonomics will accelerate clinician adoption; this includes prioritizing imaging integration, applicator modularity, and simplified source handling processes that reduce procedure time and variability. Second, companies should build robust supply-chain diversification plans that include validated alternative suppliers and regional production options to mitigate tariff and logistics volatility, coupled with transparent inventory governance tools for provider partners.

Third, commercial strategies should emphasize bundled service offerings-training, maintenance, and source management-to preserve predictable lifecycle economics for customers. Fourth, establishing formal partnerships with leading clinical centers to drive prospective evidence generation and guideline inclusion will create durable clinical preference. Finally, engaging proactively with regulators and payers to articulate safety, efficacy, and value propositions can smooth adoption pathways and align reimbursement structures with long-term patient and system benefits. Implementing these recommendations will require cross-functional commitment and measurable KPIs linked to clinical adoption and service performance.

Transparent research methodology detailing data sources, qualitative and quantitative analytical approaches, stakeholder interviews, and validation steps ensuring rigor and reproducibility

The analysis underpinning this summary was developed through a combination of primary stakeholder engagement, technical literature synthesis, and triangulation of publicly available regulatory and clinical guidance documents. Primary inputs included structured interviews with practicing radiation oncologists, medical physicists, procurement officers, and clinical engineers to validate real-world workflows, device handling pain points, and procurement rationales. Secondary inputs focused on peer-reviewed clinical outcomes literature, device safety notices, and procedural guidelines to map clinical indications to device capabilities.

Analytical methods included cross-segmentation synthesis to identify where product attributes align with clinical use-cases, scenario analysis to explore supply-chain shocks and tariff impacts, and qualitative benchmarking across competing value propositions. Validation steps comprised expert review sessions with practicing clinicians and biomedical engineers to confirm technical accuracy and applicability of recommendations. Wherever possible, assertions were corroborated by multiple independent sources to ensure robustness and relevance to decision-makers across clinical, procurement, and corporate strategy functions.

Concise conclusion synthesizing strategic implications, operational risks, and priority opportunities for clinical, commercial, and regulatory stakeholders

In conclusion, brachytherapy devices occupy a strategic niche in oncology care where precision, organ preservation, and procedural efficiency intersect. The combination of technological refinements in delivery systems, evolving regulatory expectations, and payer emphasis on value-based outcomes creates both opportunity and complexity for device developers and clinical adopters. Supply-chain pressures and tariff-induced cost dynamics require proactive mitigation strategies, while regionally tailored approaches to training and service delivery will determine the pace and quality of adoption across diverse healthcare systems.

Stakeholders that successfully integrate clinical evidence generation, modular product design, and resilient commercial models will be best positioned to capture long-term clinical partnerships. By focusing on interoperability with existing oncology workflows, enhancing user-centric design, and investing in collaborative evidence programs with leading clinical centers, organizations can translate innovation into measurable clinical and operational value. The path forward emphasizes pragmatic innovation that addresses daily procedural realities as much as it advances long-term therapeutic goals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brachytherapy Devices Market, by Product Type

  • 8.1. High Dose Rate
  • 8.2. Low Dose Rate
  • 8.3. Pulsed Dose Rate

9. Brachytherapy Devices Market, by Source Type

  • 9.1. Cs-137
  • 9.2. I-125
  • 9.3. Ir-192
  • 9.4. Pd-103

10. Brachytherapy Devices Market, by Application

  • 10.1. Breast Cancer
  • 10.2. Cervical Cancer
  • 10.3. Ocular Tumors
  • 10.4. Prostate Cancer

11. Brachytherapy Devices Market, by End User

  • 11.1. Ambulatory Surgical Centres
  • 11.2. Cancer Research Centers
  • 11.3. Hospitals

12. Brachytherapy Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Brachytherapy Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Brachytherapy Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Brachytherapy Devices Market

16. China Brachytherapy Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Becton, Dickinson and Company
  • 17.6. Biobot Surgical Pte Ltd.
  • 17.7. Boston Scientific Corporation
  • 17.8. C4 Imaging LLC
  • 17.9. Carl Zeiss AG
  • 17.10. CivaTech Oncology
  • 17.11. Dexur Inc.
  • 17.12. Eckert & Ziegler BEBIG S.A.
  • 17.13. Elekta AB
  • 17.14. General Electric Company
  • 17.15. Guangzhou Perception Vision Medical Technologies Co.,Ltd.
  • 17.16. Hologic Inc.
  • 17.17. iCAD, Inc.
  • 17.18. IsoAid, LLC
  • 17.19. Merit Medical Systems, Inc.
  • 17.20. Mick Radio-Nuclear Instruments Inc.
  • 17.21. Panacea Medical Technologies Pvt. Ltd.
  • 17.22. Perspective Therapeutics
  • 17.23. Qfix
  • 17.24. SeeDOS Ltd.
  • 17.25. Siemens Healthineers AG
  • 17.26. Sun Nuclear Corporation
  • 17.27. Theragenics Corporation
  • 17.28. Valco Instruments Company Incorporated
  • 17.29. Varian Medical Systems Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRACHYTHERAPY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRACHYTHERAPY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BRACHYTHERAPY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BRACHYTHERAPY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY HIGH DOSE RATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY HIGH DOSE RATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY HIGH DOSE RATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY LOW DOSE RATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY LOW DOSE RATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY LOW DOSE RATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PULSED DOSE RATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PULSED DOSE RATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PULSED DOSE RATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CS-137, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CS-137, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CS-137, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY I-125, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY I-125, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY I-125, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY IR-192, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY IR-192, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY IR-192, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PD-103, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PD-103, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PD-103, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY OCULAR TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY OCULAR TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY OCULAR TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS BRACHYTHERAPY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GCC BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. GCC BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. G7 BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. G7 BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. G7 BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. G7 BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. G7 BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NATO BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NATO BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NATO BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NATO BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NATO BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRACHYTHERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES BRACHYTHERAPY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED STATES BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA BRACHYTHERAPY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA BRACHYTHERAPY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. CHINA BRACHYTHERAPY DEVICES MARKET SIZE, BY SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA BRACHYTHERAPY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA BRACHYTHERAPY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)